Acting FDA Commissioner Woodcock defends aducanumab approval
Woodcock said she wasn’t involved in the decision, and that the data were ‘solid’
Acting FDA Commissioner Janet Woodcock strongly defended the agency’s accelerated approval of Biogen’s Aduhelm aducanumab Tuesday, in an interview with BioCentury.
Woodcock, who said she wasn’t personally involved in making the decision, said it fits squarely within the agency’s standards for accelerated approval. ...